Imaging of Chemotherapy-related Iatrogenic Abdominal and Pelvic Conditions

Radiologic Clinics of North America

Volumn 52, Issue 5, 2014, Pages 1029-1040

  Viswanathan, Chitra ^a   Truong, Mylene ^a   Sagebiel, Tara ^a   Garg, Naveen ^a   Bhosale, Priya ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Abdomen; Complication; Cytotoxic chemotherapy; Pelvis; Targeted therapy; Toxicity

Indexed keywords

AFLIBERCEPT; ASPARAGINASE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; IPILIMUMAB; IRINOTECAN; LETROZOLE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PONATINIB; SORAFENIB; SUNITINIB; TALIMOGENE LAHERPAREPVEC; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

ABDOMINAL DISEASE; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE PANCREATITIS; ADRENAL HYPERPLASIA; ADRENAL INSUFFICIENCY; ANASARCA; ANASTOMOSIS LEAKAGE; AORTA THROMBOSIS; ARTERIAL THROMBOEMBOLISM; ASCITES; BILE DUCT CARCINOMA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CHOLECYSTITIS; CHRONIC MYELOID LEUKEMIA; COLITIS; COLOCUTANEOUS FISTULA; COLORECTAL CANCER; COLORECTAL CARCINOMA; COLORECTAL FISTULA; COLOVAGINAL FISTULA; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS MELANOMA; DIAGNOSTIC IMAGING; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; ENTERITIS; ENTEROCOLITIS; ENTEROCUTANEOUS FISTULA; FAILURE TO THRIVE; FATTY LIVER; FISTULA; GASTROCOLIC FISTULA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEMATOMA; HEMORRHAGIC CYSTITIS; HEPATITIS; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOPHYSITIS; INTESTINE ISCHEMIA; INTESTINE PERFORATION; KIDNEY CARCINOMA; LEUKEMIA; LIMB WEAKNESS; LIVER CELL CARCINOMA; LIVER FOCAL NODULAR HYPERPLASIA; LIVER VENOOCCLUSIVE DISEASE; LUNG CANCER; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVARY TUMOR; PANCREAS CANCER; PANCREATITIS; PELVIC DISEASE; PERFORATION; PERITONEUM CANCER; PLEURA EFFUSION; PNEUMATOSIS INTESTINALIS; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RECTOVAGINAL FISTULA; RETROPERITONEAL DISEASE; RETROPERITONEAL INFILTRATION; REVIEW; SPLEEN INFARCTION; SPLEEN RUPTURE; SPLENOMEGALY; STOMACH CARCINOMA; THROMBOCYTOPENIA; THROMBOEMBOLISM; TUMOR BLEEDING; UVEITIS; VENOUS THROMBOEMBOLISM; ABDOMEN; CHEMICALLY INDUCED DISORDER; COMPLICATION; CYTOTOXIC CHEMOTHERAPY; DIGESTIVE SYSTEM DISEASE; IATROGENIC DISEASE; METHODOLOGY; PELVIS; TARGETED THERAPY; TOXICITY; URINARY TRACT DISEASE;

ABDOMEN; COMPLICATION; CYTOTOXIC CHEMOTHERAPY; PELVIS; TARGETED THERAPY; TOXICITY;

ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM DISEASES; HUMANS; IATROGENIC DISEASE; UROLOGIC DISEASES;

EID: 84907980714     PISSN: 00338389     EISSN: 15578275     Source Type: Journal    
DOI: 10.1016/j.rcl.2014.05.008     Document Type: Review

References (52)

1. American Cancer Society Chemotherapy principles 2013, American Cancer Society, Atlanta (GA), [updated February 07, 2013; cited January 5, 2014]. Available at:. http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/chemotherapy/chemotherapyprinciplesanin-depthdiscussionofthetechniquesanditsroleintreatment/chemotherapy-principles-types-of-chemo-drugs.
2. Chikarmane S.A., Khurana B., Krajewski K.M., et al. What the emergency radiologist needs to know about treatment-related complications from conventional chemotherapy and newer molecular targeted agents. Emerg Radiol 2012, 19(6):535-546.
3. National Cancer Institute Targeted cancer therapies 2012, National Cancer Institute, Bethesda (MD), [cited January 05, 2014]. Available at:. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted.
4. Boussios S., Pentheroudakis G., Katsanos K., et al. Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol 2012, 25(2):106-118.
5. Beck K.E., Blansfield J.A., Tran K.Q., et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. JClin Oncol 2006, 24(15):2283-2289.
6. Thornton E., Howard S.A., Jagannathan J., et al. Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients. Br J Radiol 2012, 85(1018):1420-1426.
7. Kim K.W., Ramaiya N.H., Krajewski K.M., et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol 2013, 200(5):W468-W474.
8. Coriat R., Ropert S., Mir O., et al. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs 2011, 29(5):1090-1093.
9. Abu-Hejleh T., Mezhir J., Goodheart M., et al. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep 2012, 14(4):277-284.
10. Borofsky S.E., Levine M.S., Rubesin S.E., et al. Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients. Abdom Imaging 2013, 38(2):265-272.
11. Chow H., Jung A., Talbott J., et al. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. JComput Assist Tomogr 2011, 35(1):86-90.
12. Tirumani S., Baez J., Jagannathan J., et al. Tumor-bowel fistula: what radiologists should know. Abdom Imaging 2013, 38(5):1014-1023.
13. Zavaglia C., Airoldi A., Mancuso A., et al. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Eur J Gastroenterol Hepatol 2013, 25(2):180-186.
14. Je Y., Schutz F.A., Choueiri T.K. Risk of bleeding withvascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009, 10(10):967-974.
15. Han G., Zhao Y., Qi X., et al. Hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011, 34(11-12):1347-1348.
16. Liu Y., Zhang H.L., Zhang Y., et al. Digestive tract hemorrhage due to complications with gastrointestinal stromal tumor treated with sunitinib: a case report. Oncol Lett 2013, 5(2):699-701.
17. Hu Y., Wang J., Tao H., et al. Increased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trials. PLoS One 2013, 8(9):e74872.
18. Asnacios A., Naveau S., Perlemuter G. Gastrointestinal toxicities of novel agents in cancer therapy. Eur J Cancer 2009, 45(Suppl 1):332-342.
19. Jeong W.K., Choi S.Y., Kim J. Pseudocirrhosis as a complication after chemotherapy for hepatic metastasis from breast cancer. Clin Mol Hepatol 2013, 19(2):190-194.
20. Jha P., Poder L., Wang Z.J., et al. Radiologic mimics of cirrhosis. AJR Am J Roentgenol 2010, 194(4):993-999.
21. Young S.T., Paulson E.K., Washington K., et al. CT of the liver in patients with metastatic breast carcinoma treated by chemotherapy: findings simulating cirrhosis. AJR Am J Roentgenol 1994, 163(6):1385-1388.
22. Overman M.J., Maru D.M., Charnsangavej C., et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. JClin Oncol 2010, 28(15):2549-2555.
23. Rubbia-Brandt L., Lauwers G.Y., Wang H., et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010, 56(4):430-439.
24. Shanbhogue A.K., Virmani V., Vikram R., et al. Spectrum of medication-induced complications in the abdomen: role of cross-sectional imaging. AJR Am J Roentgenol 2011, 197(2):W286-W294.
25. Iannaccone R., Federle M.P., Brancatelli G., et al. Peliosis hepatis: spectrum of imaging findings. AJR Am J Roentgenol 2006, 187(1):W43-W52.
26. Morris-Stiff G., Tan Y.M., Vauthey J.N. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol 2008, 34(6):609-614.
27. Khan A.Z., Morris-Stiff G., Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. JHepatobiliary Pancreat Surg 2009, 16(2):137-144.
28. Howard S.A., Krajewski K.M., Thornton E., et al. Decade of molecular targeted therapy: abdominal manifestations of drug toxicities-what radiologists should know. AJR Am J Roentgenol 2012, 199(1):58-64.
29. Abdalla E.K., Vauthey J.N. Chemotherapy prior to hepatic resection for colorectal liver metastases: helpful until harmful?. Dig Surg 2008, 25(6):421-429.
30. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. JClin Oncol 2006, 24(13):2065-2072.
31. Torrisi J.M., Schwartz L.H., Gollub M.J., et al. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 2011, 258(1):41-56.
32. Kim K.W., Ramaiya N.H., Krajewski K.M., et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013, 31(4):1071-1077.
33. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) 2013, 2013:19.
34. Jayakrishnan T.T., Groeschl R.T., George B., et al. Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis. Ann Surg Oncol 2014, 21(1):240-247.
35. Veerappan R., Morrison M., Williams S., et al. Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature. Bone Marrow Transplant 2007, 40(4):361-364.
36. Kim S.O., Han S.Y., Baek Y.H., et al. Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient. World J Gastroenterol 2011, 17(2):267-270.
37. Malka D., Van Den Eynde M., Boige V., et al. Splenic infarction and bevacizumab. Lancet Oncol 2006, 7(12):1038.
38. Jardim D.L., Rodrigues C.A., Novis Y.A., et al. Oxaliplatin-related thrombocytopenia. Ann Oncol 2012, 23(8):1937-1942.
39. Pezzilli R., Fabbri D., Imbrogno A., et al. Tyrosine kinase inhibitors, pancreatic hyperenzymemia and acute pancreatitis: a review. Recent Pat Inflamm Allergy Drug Discov 2011, 5(2):165-168.
40. Amar S., Wu K.J., Tan W.W. Sorafenib-induced pancreatitis. Mayo Clin Proc 2007, 82(4):521.
41. Cortes J.E., Kim D.W., Pinilla-Ibarz J., et al. Aphase 2 trial of Ponatinib in Philadelphia chromosome-positive leukemias. NEngl J Med 2013, 369(19):1783-1796.
42. Dy G.K., Adjei A.A. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013, 63(4):249-279.
43. Hecker A., Hecker B., Bassaly B., et al. Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review. World J Surg Oncol 2010, 8:47.
44. Masiello D., Gorospe G., Yang A.S. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. JHematol Oncol 2009, 2:46.
45. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004, 9(3):271-281.
46. Richards C.J., Je Y., Schutz F.A., et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. JClin Oncol 2011, 29(25):3450-3456.
47. Bronstein Y., Ng C.S., Hwu P., et al. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. Am J Roentgenol 2011, 197(6):W992-W1000.
48. Turan N., Benekli M., Ozturk S.C., et al. Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor. Ann Pharmacother 2012, 46(10):e27.
49. Pallotti M.C., Pantaleo M.A., Nannini M., et al. Development of a nephrotic syndrome in a patient with gastrointestinal stromal tumor during a long-time treatment with sunitinib. Case Rep Oncol 2012, 5(3):651-656.
50. Ribeiro R.A., Lima-Junior R.C., Leite C.A., et al. Chemotherapy-induced hemorrhagic cystitis: pathogenesis, pharmacological approaches and new insights. JExp Integr Med 2012, 2(2):95-112.
51. McCarville M.B., Hoffer F.A., Gingrich J.R., et al. Imaging findings of hemorrhagic cystitis in pediatric oncology patients. Pediatr Radiol 2000, 30(3):131-138.
52. Grenader T., Shavit L. Chemotherapy-induced adrenal crisis. Int J Oncol 2005, 3(1):6.